Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study Ignacio Marín-Jiménez; Manuel Barreiro-de Acosta; María Esteve; Luisa Castro-Laria; Santiago García-López; Daniel Ceballos; Ana Echarri; María Dolores Martín-Arranz; David Busquets; Jordina Llaó; Mercè Navarro-Llavat; José María Huguet; Federico Argüelles-Arias; Raquel Vicente; José Miguel Boudet; Gema Díaz; Ana M. Sánchez-Migallón; Francesc Casellas;

Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease Mariam Aguas Peris; Javier del Hoyo Francisco; Pilar Nos Mateu; Ana Echarri Piudo; Marta Calvo Moya; Beatriz Gros; María Dolores Martín-Arranz; Emilio Monte Boquet; Sergio Inglán Agustín; Antonio Valdivia Martínez; Marisa Correcher; Manuel Barreiro-de Acosta; Miriam Mañosa Ciria; Francisco Rodriguez-Moranta; Yamile Zabana; Ana Gutiérrez Casbas;

Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease Carmen Amor Costa; Cristina Suárez Ferrer; Laura García Ramírez; Eduardo Martín-Arranz; Joaquín Poza Cordón; José Luis Rueda García; María Sánchez Azofra; Irene González Diaz; Clara Amiama Roig; María Dolores Martín-Arranz;